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Biomarkers in Renal Vasculitis
Polyvios Arseniou, Stamatia Stai and Maria Stangou
Abstract
The use of biomarkers in glomerular diseases has been subject of investigation 
during the last decades, as it can provide worthwhile evidence in diagnosis, but also, 
it can guide treatment and give information about prognosis and response. Renal 
biopsy is still the compulsory technique to establish diagnosis, and also to offer 
information about the severity of renal damage. However, as an invasive method, it 
cannot be regularly performed during follow up, so the need to find and establish 
measurement of molecules, easily collected, which are associated with disease 
pathogenesis and predict renal function outcome seems very attractive to nephrolo-
gists. The renal complications of systemic vasculitis are very important for the 
outcome of the disease, and several substances and molecules, such as inflamma-
tory cells, autoantibodies, cytokines, chemokines and growth factors are produced 
and may serve as biomarkers to provide useful information for diagnosis, follow up 
of the disease.
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1. Introduction
The classical presentation of a primary or secondary glomerular disease (GD) is 
the triad of microscopic hematuria, proteinuria and impaired renal function.
A patient who presents with microhematuria, 2 g of proteinuria and a GRF of 
around 35 ml/min is possible to have IgAN, focal segmental sclerosis (FSGS) or 
membranous nephropathy (MN) or focal necrotising glomerulonephritis, due to 
vasculitis, and the diagnosis will be established with renal biopsy, which is the typi-
cal and standard method in diagnosing GN.
However, renal biopsy is an invasive method, which is usually mandatory for 
diagnosis, but, carrying the probability of complications, it cannot be repeated 
regularly during follow up. This is the reason, why the need to find and apply 
biomarkers that could help in diagnosis and follow up of the GNs is imperative.
2. Biomarkers: which are the characteristics of an ideal biomarker?
The precise characteristics of an ideal biomarker depend upon the disease of 
investigation, but certain features are considered as important, and are depicted in 
Table 1.
Primary and secondary GDs have some unique advantages; first of all kidneys 
produce urine, and urine are easy to collect in order to repeat measurements during 
follow up, but also excreted molecules in the urine represent histological changes 
in the kidneys. Nevertheless, kidneys are highly perfused organs, meaning that any 
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substances in the serum may have a direct effect on them. On the other hand, there 
are major disadvantages. Pathogenesis of GDs, especially of vasculitis affecting 
kidneys, is not a simple issue, it is complicated and in most cases not completely 
identified. Histological lesions are the result of different synergistic or counteract-
ing pathways, which lead to proliferation, inflammation and fibrosis. In addition, 
the same molecule will not have the same effect in all glomerular diseases [1–5].
All the above mean that all the information provided by kidney biopsy cannot 
be easily substituted by one biomarker, and the question that comes up is: do the 
biomarkers have something to offer which is beyond the renal biopsy results and 
beyond the classical approach of glomerular diseases, including estimation of renal 
function impairment, degree of proteinuria, microhematuria and active urine sedi-
ment, or do they just correlate with these parameters and reflect renal damage?
In the present chapter, we are going to describe biomarkers involved in patho-
genesis and outcome of systemic vasculitis affecting the kidneys, and we shall 
investigate possible advantage instead of using classical parameters.
3. ANCA-associated vasculitides
ANCA-associated vasculitides (AAV) are a group of systemic pauci-immune 
diseases, characterized by inflammatory necrosis of the small vessels (arterioles, 
capillaries and venules) and the presence of antineutrophil cytoplasmic antibodies 
(ANCA) [6–11]. There are four clinical and pathological phenotypes of AAV: granu-
lomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis), 
eosinophilic granulomatosis with polyangiitis (EGPA, also known as Churg-Strauss 
syndrome), microscopic polyangiitis (MPA) and, finally, renal limited vasculitis 
(RLV), also known as idiopathic rapidly progressive glomerulonephritis (RPGN) 
[9, 11]. Contrary to other small-vessel vasculitides, which are immune-complex-
mediated, in AAV there is no significant immunoglobulin deposition [6, 9–11].
4. ANCA
ANCA are IgG autoantibodies directed against proteinase 3 (PR3-ANCA), 
expressed in neutrophil granules, and myeloperoxidase (MPO-ANCA), expressed 
in monocyte lysosomes. PR3 and MPO are also expressed in the neutrophil 
extracellular traps (NET), localized to inflammatory lesions within the affected 
organs [6–11]. Because of their immunofluorescence pattern, PR3-ANCA are also 
described as cytoplasmic ANCA (c-ANCA), whereas MPO-ANCA are referred to as 
perinuclear ANCA (p-ANCA) [5, 9–11]. Indirect immunofluorescence and enzyme-
linked immunosorbent assay (ELISA) methods are used to detect ANCA in the 
1. High sensitivity
2. High specificity
3. Biological plausibility
4. Associated with pathogenic mechanisms
5. Prognosis and response to treatment
6. Biomarker sources should be easily available
Table 1. 
Specific characteristics, an ideal biomarker should carry.
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serum of patients [9, 11]. The type of ANCA (PR3-ANCA or MPO-ANCA) defines 
the serotype of the AAV [8, 11].
There is a correlation between the serotype and the phenotype of AAV. PR3-
ANCA are most common (75%) in patients with GPA and least common (5%) in 
patients with EGPA. MPO-ANCA occur more frequently in patients with RLV (70%), 
while they appear in 60% of patients with EGPA and 50% of patients with MPA. The 
occurrence of seronegativity is 5 and 30% in GPA and EGPA, respectively, and 10% 
in MPO and RLV [9]. ANCA-positive patients present either PR3-ANCA or MPO-
ANCA, whereas the occurrence of both ANCA in the same individual is extremely 
rare and related to infection-induced or drug-mediated vasculitis [5, 9–11].
However, autoantibodies against different antigenic targets, such as lysosome-
associated membrane protein-2 (LAMP-2), plasminogen, moesin, have been dem-
onstrated recently, and they were related to different precipitating causes, as well 
as different disease presentation and severity. Specifically, anti-LAMP-2 antibodies 
have been found in most patients with RLV linked to E. coli urinary tract infection 
(UTI), suggesting that molecular mimicking mechanisms may be responsible for 
the formation of antibodies [6–10].
5. Pathogenesis
PR3 and MPO antigens are presented by autoreactive antigen-presenting B cells to 
autoreactive T cells, thus stimulating their activation and polarization, with the forma-
tion of pro-inflammatory Th1, Th2 and Th17 cells. In that environment, T cells activate 
B cells, promoting the formation of ANCA. Autoreactivity of B and T cells is presented 
in patients with genetic susceptibility, as shown by correlation of the disease with spe-
cific HLA gene loci, while both SNP in certain genes and epigenetic factors are associ-
ated with increased antigenic expression in neutrophils and monocytes. That increased 
expression of PR3 on the monocyte cell surface causes macrophage activation, while 
binding of MPO-ANCA promotes the release of pro-inflammatory cytokines, such as 
IL-1β, IL-6 and IL-8. On the other side, increased PR3 expression on the neutrophil 
surface, in patients with GPA, promotes diminished macrophage phagocytosis of neu-
trophils that have undergone apoptosis, leading to uncontrolled necrosis and release of 
more antigens and pro-inflammatory cytokines, including IL-6, IL-8 and TNF-α, which 
further amplify the previous pathological immune mechanism [6–11].
The involvement of immune cells in pathogenesis of AAV, through impaired 
immune tolerance and balance between immune response and immune regulation is 
crucial. As mentioned, B cells are responsible for antigen presentation and antibody 
production, but also for cytokine production and activation of T cells. That is why 
rituximab, a chimeric monoclonal anti-CD20 antibody, is successfully administered 
as therapy for AAV. Besides that, regulating B cells, which act suppressing immune 
response, are found numerically normal, but with impaired function. This also 
applies for regulating T cells, while, on the contrary, effector T cells are found infil-
trating affected tissues, alongside with macrophages, neutrophils and monocytes. 
These cells are responsible for direct tissue damage, releasing reacting oxygen species. 
Neutrophils, specifically, appear to be the main participating cell in vessel damage, via 
the respiratory burst and the release of proteolytic enzymes and NET [6–11].
There are recent data from animal and patient studies suggesting that the 
complement is also involved in AAV. Altered levels of C3, C4, and CH50 are found 
in some patients during presentation and are associated with adverse outcome. 
Moreover, C5a and its receptor are implicated in neutrophil activation, thus estab-
lishing the alternative compliment pathway as a promoting disease factor and a 
possible therapeutic target [6–11].
Glomerulonephritis and Nephrotic Syndrome
4
As far as genetic susceptibility is concerned, genome-wide association studies 
(GWAS) have documented a close relation between the phenotype and serotype 
of AAV and specific HLA gene loci. In detail, studies on Northern European and 
American populations have shown that GPA and PR3-ANCA are strongly associated 
with HLA-DP loci (with HLA-DP 0401 being associated with PR3-ANCA vasculitis 
and recurrence of disease, regardless of phenotype or serotype), while MPO-ANCA 
are related to HLA-DQ loci. HLA-DR B1501 is associated with AAV presentation in 
African American patients and HLA-DR B4 with EGPA. Besides HLA genes, SNP 
in genes PRTN3, coding for PR3, and SERPINA1, coding for a1-antitrypsin (A1AT), 
a protein regulating PR3, are associated with the formation of PR3-ANCA, while 
SNP in gene PTPN22, coding for a protein tyrosine phosphatase, regulating B and T 
cell receptor-mediated cell activation, is implicated in the dysregulation of immune 
response [6–11].
6. Clinical presentation
AAV is, as mentioned before, a necrotizing inflammation of the small vessels. 
Therefore, it is considered a systemic disorder, affecting all tissues and organs. The 
clinical presentation depends on the activity and the chronicity of the disease and 
the specific system involvement and determines, together with the pathology, the 
phenotype of the disease [9].
The onset of the disease may be accompanied by non-specific systemic symp-
toms, such as fever, fatigue, malaise, anorexia, weight loss, arthralgia and myalgia. 
These symptoms, reminiscent of flu-like illness, may precede weeks or even months 
before the occurrence of specific systemic manifestations [9, 12].
Renal involvement is the most significant and severe of AAV clinical presenta-
tion. It affects almost every patient with MPA (90%) and GPA (80%), but less 
than half of the patients with EGPA (45%). The most common presentation is with 
RPGN, thus featuring typically microscopic or gross hematuria, subnephrotic 
proteinuria, hypertension, edema and, finally, renal failure, while examination 
of the urine reveals active urinary sediment, with dysmorphic red blood cells and 
red blood cell casts. Another presentation, common to patients with MPO-ANCA, 
is indolent glomerulonephritis, featuring a more chronic presence of microscopic 
hematuria and a slower decline of renal function. Interestingly, 5% of the patients 
with ANCA vasculitis (mostly MPO-ANCA) are also positive for anti-glomerular 
base membrane (anti-GBM) antibodies, suggesting concomitant glomerular lesions 
of AAV and anti-GBM disease. Renal involvement is the only manifestation of RLV 
[9, 11, 12].
Lower respiratory system involvement is more frequent in GPA (90%) and 
EGPA (70%) and less frequent in MPA (50%). Pulmonary manifestations vary 
from transient infiltration of the alveoli to severe pulmonary hemorrhage. Clinical, 
laboratory and imaging findings include dyspnea, cough, hemoptysis, acid-base 
balance and blood gases disorder, lung functional tests disorder, as well as radiologi-
cal ground-glass pattern, with nodules and diffuse infiltrates [9, 11, 12].
Upper respiratory system is also involved in the clinical presentation, concerning 
mostly patients with GPA (90%), but also half of the patients with EGPA and 35% 
of the patients with MPA. Patients present sinusitis, rhinitis, ocular inflammatory 
disorders, such as episcleritis, necrosis and perforation of the nasal septum and 
subglottic stenosis. Interestingly, EGPA, is less associated with RPGN and pulmo-
nary hemorrhage and is characterized by a prodromal phase of atopic manifesta-
tions, asthma and allergic rhinitis, followed by an eosinophilic phase of increased 
eosinophil counts in the blood and eosinophilic perfusion of affected tissues, before 
evolving to active vasculitis [9, 11, 12].
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Involvement of the central and peripheral nervous system accompanies 70% of 
patients with EGPA, 50% of patients with GPA and 30% of patients with MPA and 
manifests usually as mononeuritis multiplex, while the inflammation of the menin-
ges is less frequent [9, 11, 12].
Cardiovascular involvement, mainly in ANCA-negative EGPA patients, presents as 
endocarditis, pericarditis or myocarditis, hypokinesis of the ventricles arrhythmias, such 
as atrioventricular blocks, and, lastly, as acute myocardial infarction [9, 11, 12].
Gastrointestinal involvement, affecting half of the patients with AAV, presents 
as an acute abdomen, with abdominal pain, hematochezia and sometimes even 
perforation, due to mesenterial ischemia and ulceration [9, 12].
Finally, AAV present with a plethora of cutaneous lesion, such as purpura, 
petechiae, ecchymoses, ulcers, nodules and more [9].
7. Renal pathology
Renal biopsy is the gold standard for the diagnosis of renal disease, and this also 
applies for AAV. The classical histopathological feature in renal biopsy of AAV patients 
Figure 1. 
Histology of renal involvement in ANCA associated vasculitis (A) and IgAV-N (B).
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is segmental necrotizing glomerulonephritis. Characteristic findings include inflamma-
tory perfusion of both glomeruli and interstitial tissue, fibrinoid necrosis of glomeruli, 
glomerular capillary obstruction and crescents. Granulomas are also found in GPA and 
EGPA. It is worth mentioning again that, because AAV are pauci-immune vasculitides, 
immunofluorescence is negative, that meaning there is a paucity or absence of glo-
merular immune deposits. Nevertheless, there are patients who demonstrate atypical 
histopathological features, such as interstitial nephritis with vasa recta vasculitis. These 
patients eventually develop the classical lesions of AAV [9, 11, 12] (Figure 1).
8. Biomarkers in AAV
Any substance that can be objectively measured and evaluated as an indicator 
of normal and pathogenic processes or response to an intervention can be used as a 
biomarker [13].
Inflammatory markers, such as erythrocyte sedimentation rate (ESR) and 
c-reactive protein (CRP), are non-specific and, although they can be used in the 
diagnosis of AAV, when evaluated together with clinical and pathological presenta-
tion, they are of no value in the differential diagnosis and assessment of disease 
activity and relapse in diagnosed patients [14].
On the contrary, research on platelet (PLT) counts, which are an acknowledged 
inflammatory marker, found elevated PLT counts in patients with active disease, 
compared to patients in remission, and also elevated PLT counts in AAV patients 
with active disease, compared to AAV patients with infection, thus highlighting 
their role as an AAV specific marker of disease activity [15].
9. ANCA as biomarkers
Although ANCA are important in the diagnosis of AAV, there are seronega-
tive patients with clinically and pathologically established disease. Furthermore, 
because diagnosed patients tend to remain ANCA-positive during clinical remis-
sion, the use of ANCA as a marker of disease activity and relapse is also limited. 
Nevertheless, increased values of ANCA in seropositive patients or emergence in 
seronegative patients, can be evaluated as a marker of disease relapse [14]. Studies 
have suggested that increase of ANCA titer should not be taken into consideration 
in terms of changing treatment decisions, but could be used to select patients 
requiring closer monitoring [14, 16].
10. LAMP-2
Unlike PR3 and MPO, LAMP-2 is also expressed in glomerular endothelial cells, 
an important site of inflammatory injury [17]. As mentioned before, anti-LAMP-2 
antibodies are believed to be formatted through molecular mimicking of bacterial 
proteins, proposing the implication of this mechanism in the pathogenesis of disease.
One study indicated that anti-LAMP-2 antibodies are present in 80–90% of 
untreated patients, including PR3-ANCA negative and MPO-ANCA negative 
patients, while being undetected in healthy controls. Interestingly, anti-LAMP-
2antibodies become rapidly undetectable after immunosuppressive therapy, thus 
suggesting a possible role in the diagnosis and monitoring of AAV patients. However, 
these findings were not replicated by other investigators, meaning that the use of 
these antibodies as a biomarker of disease activity is rather inappropriate [10, 14, 17].
7Biomarkers in Renal Vasculitis
DOI: http://dx.doi.org/10.5772/intechopen.86489
11. Plasminogen
The presence of anti-plasminogen antibodies, in about 18–26% of AAV patients, 
depending on the study, is strongly correlated with glomerular lesion severity, but 
only weakly correlated with ESR, renal function and renal histopathology [14].
12. Moesin
Moesin, a heparin-binding protein linking actin to the plasma membrane of the 
cellular cortex, is identified as a possible molecule responsible for the formation 
of MPO-ANCA, using molecular-mimicking mechanisms, similarly to LAMP-2. 
Anti-moesin antibodies are found increased in both active AAV disease and remis-
sion, but are associated with renal damage, as assessed by correlation to blood urea 
nitrogen, serum creatinine and proteinuria [14, 18].
13. NET
The contribution of NET in the pathogenesis of AAV is already mentioned. 
Excessive NET formation is observed in both PR3-ANCA and MPO-ANCA positive 
patients with active AAV compared to healthy individuals, which is interestingly 
independent of ANCA titers. Moreover, excessive NET formation is presented in 
hospitalized AAV patients for disease relapse, but not for infection, suggesting a 
specificity of NET as a marker of autoimmunity, rather than infection [19].
14. Leucocytes
Regulatory B cells (Bregs) have been investigated as a potential biomarker of 
AAV. A research group found CD25+ B cells to be increased during disease remission, 
compared to active disease and healthy controls. Another study revealed CD5+ B cells 
numerical deficiency in AAV patients, compared to healthy controls. These data, 
however, are insufficient for the establishment of Bregs as biomarkers in AAV [14, 17].
A study attempted to clarify the role of CD8+ T cells as a biomarker of AAV. The 
presence of particular gene expression profiles of CD8+ T cells were associated with 
disease relapse, among patients with the same disease activity, inflammatory mark-
ers and treatment. If validated, these data could be used to identify patients in need 
of customized therapeutic regimens [14, 17, 20].
Regulatory T cells (Tregs) have also been studied by researchers. Decreased 
number and impaired functionality of Tregs was found in patients with active 
AAV. Furthermore, the proportion of Tregs was found inversely correlated with 
relapse and positively associated with time of remission. Based on these data, Tregs 
could be used as a biomarker of therapeutic and prognostic importance [14, 17].
15. Monocytes
The role of monocytes in the pathogenesis and tissue damage in AAV has 
already been discussed. Soluble and cell surface markers of monocyte activation 
are increased in AAV patients, even during disease remission. Furthermore, 
monocyte-derived macrophages and giant cells within affected tissues and 
granulomas may be responsible for maintaining autoimmunity. These data suggest 
Glomerulonephritis and Nephrotic Syndrome
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that monocytes may account for disease relapse, thus be used as a prognostic 
biomarker of negative outcome [21].
16. Inflammatory response
• Complement: Plasma levels of C3a, C5a, soluble C5b-9 and Bbare found 
increased in patients with active disease, compared to patients with disease 
remission and healthy controls [14, 17]. C5a receptor (C5aR) expres-
sion is found lower in renal tissue of patients with active disease [17, 22]. 
Furthermore, plasma levels of Bb, which is indicative of alternative pathway 
activation, is associated with serum inflammatory markers and the presence 
of crescents in renal biopsy. Similarly, urinary levels of Bb are positively 
correlated with serum creatinine levels, indicative of renal function, and 
negatively correlated with the percentage of normal glomeruli in renal 
biopsy [14, 17].
• Monocyte chemotactic protein-1: Monocyte chemotactic protein-1 (MCP-1), 
as declared by its name, affects the monocyte/macrophage migration to the 
tissues. It is also related to the number of circulating monocytes and T cells. 
Serum MCP-1 is measured significantly higher in patients with AAV, compared 
to healthy controls. Interestingly, in AAV patients, MCP-1 is found elevated 
in those with renal involvement, compared to patients without renal involve-
ment. Moreover, serum MCP-1 levels are correlated with serum creatinine 
levels and proteinuria severity [23].
• Calprotectin: Calprotectin is a heterodimer complex of two calcium-binding 
proteins, expressed on neutrophils, monocytes and early differentiated 
macrophages [14, 24]. Serum calprotectin is found increased in patients with 
active AAV and decreased, but not normalized, during remission, thus impli-
cating subclinical disease [24]. Calprotectin levels are, additionally, elevated 
in patients who discontinued treatment [24] and in patients who relapsed [9, 
19], with the elevation predictive of relapse happening during remission [14]. 
Correlation between calprotectin expression and renal biopsy indicates higher 
expression of calprotectin in patients with focal lesions and crescents and 
lower expression in patients with sclerotic findings. Furthermore, neutrophil 
and monocyte cell surface calprotectin expression is, also, higher in patients 
with AAV, compared to healthy individuals [24].
• Neutrophil gelatinase-associated lipocalin: Neutrophil gelatinase-associated 
lipocalin (NGAL) is a protein contained in neutrophil granules and, because 
of its primary secretion, is considered a marker of neutrophil degranulation. 
Serum levels of NGAL are higher at initial onset and disease relapse of AAV, 
compared to disease remission, thus suggesting a role in AAV diagnosis and 
evaluation of activity. Moreover, they are associated with disease severity, ESR, 
CPR and ANCA titers [25].
• Angiopoietin-2: Angiopoietin-2 (Ang-2), an important regulator of endothe-
lial activation, is also positively associated with AAV severity. However, levels 
of Ang-2 do not decline after successful therapy, thus are not predictive of 
response to therapy, and, moreover, levels during remission are not predictive 
of relapse onset [26].
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17. Other serum inflammatory proteins
Among many serum inflammatory proteins, such as cytokine, chemokines, 
soluble receptors, etc., CXCL13 (BCA-1), matrix metalloproteinase-3 (MMP-3) and 
tissue inhibitor of metalloproteinases-1 (TIMP-1) report the strongest correlation 
with AAV. Specifically, higher levels of these proteins are found in patients with 
active disease, compared to healthy individuals, and are also able to distinguish 
active disease from disease remission. Additionally, lower levels are measured after 
successful therapy of AAV [14, 27].
18. Urinary biomarkers
A study investigated the role of four urinary proteins [alpha-1 acid glycoprotein 
(AGP), kidney injury molecule-1 (KIM-1), MCP-1 and NGAL (with the last two 
being already mentioned above as serum biomarkers)] as biomarkers of active 
disease. All four proteins were found increased in the urine of patients during active 
renal disease, compared to remission, with MCP-1 being the most accurate dis-
criminator between the two [23]. MCP-1 levels were also strongly indicative of poor 
outcome and disease relapse [14, 17, 28].
Another research studied the possible use of urinary soluble CD163 (sCD163), 
secreted by monocytes and macrophages, as a biomarker in small vessel vasculitis 
(SVV). Glomeruli of patients with SVV contained remarkably higher levels of 
CD163 RNA, thus presented increased expression of CD163, than those of patients 
from disease controls (lupus nephritis, diabetic nephropathy, nephrotic syndrome) 
[29]. In addition, patients with active SSV had higher levels of urinary sCD163, 
compared to patients in disease remission [14, 29], disease controls and healthy 
controls [29].
Urinary excretion of angiogenic factors (VEGF, EGF), cytokines with known 
pro-inflammatory (IL-6, MCP-1, MIP-1b), anti-inflammatory (IL-2, IL-4, IL-15), 
and pro-fibrotic activity (TGF-β, IL-6) have been evaluated as biomarkers in renal 
Cytokine (pg/mg Ucr) RPGN
n = 38
Controls
n = 10
p
IL-2 0.003 ± 0.01 0 0.04
IL-4 0.003 ± 0.006 0.008 ± 0.001 0.04
IL-6 1.2 ± 0.03 0.001 ± 0.001 0.05
IL-8 0.94 ± 2.8 0.04 ± 0.09 0.05
IL-9 0.9 ± 0.0001 0.04 ± 0.09 0.02
IL-15 0.2 ± 0.5 0 0.03
TGF-β1 27.5 ± 79 0.02 ± 0.05 0.04
VEGF 4.3 ± 3.6 0.001 ± 0.0007 <0.0001
MCP-1 2.5 ± 0.001 0.1 ± 0.04 0.01
MIP-1β 1.6 ± 0.001 0.06 ± 0.05 0.02
EGF 0.15 ± 0.3 0.14 ± 0.07 NS
Table 2. 
Differences in the urinary excretion between patients with rapidly progressive glomerulonephritis due to 
vasculitis and controls.
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Figure 2. 
Impact of cytokines during the acute and chronic phase of vasculitis.
Figure 3. 
Favorable influence of cytokines in renal function outcome.
11
Biomarkers in Renal Vasculitis
DOI: http://dx.doi.org/10.5772/intechopen.86489
vasculitis. Most of them were significantly increased compared to controls (Table 2). 
Cytokines with possible impact to histologic findings were TGF-β1, IL-15, MCP-1, 
MIP-1b and EGF. Several factors, such as IL-6, VEGF, MIP-1b and IL-15 could predict 
worse outcome of renal function, while others, including EGF, IL-2 and IL-9 were 
correlated with a favorable outcome (Figures 2 and 3). The above findings suggested 
that these factors may act synergistically or competitively during the progression of 
the disease [30, 31].
19. IgA vasculitis-nephritis
Immunoglobulin A vasculitis-nephritis (IgAV-N), formerly known as Henoch-
Schonlein purpura nephritis (HSPN) is the most common vasculitis in childhood, 
with an annual incidence of 13–20/100,000 children under 17 years of age, but 
also affects adults and elderly patients with increasing incidence. IgAV is a small 
vessel vasculitis, usually presents by palpable purpura on the lower legs, arthritis, 
abdominal pain, and nephritis, while less frequent are manifestations from pul-
monary involvement, such as alveolar hemorrhage and neurologic involvement 
[32–34].
Diagnosis of the IgAV-N is mainly based on the criteria defined by The European 
League Against Rheumatism (EULAR), Paediatric Rheumatology International 
Trials Organization (PRINTO) and Paediatric Rheumatology European Society 
(PRES) (EULAR/PRI NTO/PRES) [35, 36].
Among children with IgAV a proportion of 20–60% will show renal complica-
tions, most of them occur at disease onset. Manifestations of renal involvement 
cover a wide spectrum of symptoms ranging from urinary abnormalities, such as 
hematuria or/and proteinuria, to rapidly progressive glomerulonephritis and acute 
kidney disease. Although disease is considered as mild and self-limited, a consider-
able proportion reaching to 15% will develop chronic kidney disease. The presence 
of nephritic syndrome, impaired renal function at presentation, increased levels 
of proteinuria, severe histology and no response to treatment are considered as 
parameters predicting adverse outcome of renal function [32, 34].
20. Renal pathology
Histology of IgAV-N is characterized by mesangial hypercellularity and mesan-
gial deposition of IgA and C3, with or without IgG. Fibrinoid necrosis and crescents 
are a common finding, while the presence of segmental or global sclerosis, endocap-
illary hyperplasia, severity of tubulointerstital fibrosis and inflammatory infiltra-
tion may vary between cases (Figure 1) [35, 36].
Several classification systems have attempted to organize histological findings 
and evaluate their significance. The classification proposed by the International 
Study of Kidney Disease in Children (ISKDC), mainly based on the presence and 
extent of crescents, is widely used, although lately there have been attempts to apply 
Oxford classification system in IgAV-N, in the same way as this is used for IgAN 
classification [35].
According to ISKDC classification, optical microscopy findings are categorized 
into six histological grades. Grades I-V are based on the extension of crescents, 
grade VI describes a membranoproliferative type glomerulonephritis. The system 
was designed to estimate vasculitic lesions and inflammation, therefore it took into 
account the state of glomeruli only and not tubulointerstitial lesions. This seems 
to be the main disadvantage of the system, as presence and percentage of crescent 
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formation merely reflect active inflammation, and their predictive value has been 
doubted in recent studies, which showed that patients on higher grades may experi-
ence spontaneous remission, while those with low grade histologic lesions may 
develop chronic renal failure [37–40].
The Oxford classification system, available since 2009, has been designed 
to estimate histology in IgAN, and it was based initially on four morphologic 
features: mesangial hypercellularity (M), endocapillary proliferation (E), 
segmental glomerulosclerosis (S) and tubular atrophy/interstitial fibrosis (T), 
which formed the MEST score [41–43]. More recently, the system was revised 
to MEST-C score, including the present of crescents, as crescent score (C) [44]. 
Although patients with IgAV-N were not included in the validation cohort, and 
therefore, the classification system cannot officially be recommend for patients 
with this condition, there have been few recent attempts to apply Oxford clas-
sification in IgAV-N. The presence of endocapillary proliferation and tubulointer-
stitial fibrosis were the main histologic findings associated with worse outcome of 
renal function [44–46].
Renal biopsy is essential for diagnosing IgAV-N, probably guide treatment and 
predict outcome, but, the procedure cannot be used repeatedly during follow up of 
the patients. The use of biomarkers is again mandatory to estimate disease outcome. 
IgAV-N share the same pathogenic pathway with IgAN, mediated by aberrant 
O-linked glycosylation of IgA1 hinge region, they are considered similar diseases 
that share common pathophysiologic mechanisms. Based on this fact, researchers 
tried to evaluate the utility of IgAN biomarkers in the assessment of the clinical 
course of IgAV-N. It was thus found that several of them could be used in IgAV-N 
patients as well [47, 48].
21. Biomarkers in IgAV-N
21.1 Serum and urine immunoglobins and immune complexes
Since IgA deposition in various tissues is an important parameter of the disease 
pathophysiology, several studies have tried to examine immunoglobin production 
in IgAV patients. It has been found that IgA and IgE serum concentrations are 
higher in individuals with IgAV compared to normal controls, although it has not 
been proven that they can be useful in distinguishing patients with and without 
nephritis [47]. Moreover, serum Gd-IgA1 and IgA-IgG complexes, as well as urine 
IgA and IgA-IgG complexes are potential biomarkers for IgAV-N. More specifically, 
elevated levels of Gd-IgA1 in the blood of IgAV patients have been correlated with 
the presence of nephritis [47]. It has been proposed that recognition of the under 
galactosylated IgA1 hinge region by IgA or IgG antibodies induces the production 
of circulating immune complexes [47, 48]. Indeed, high concentrations of IgA-IgG 
complexes have been found in the serum of all IgAV-N patients, while in urine, the 
levels of these complexes are increased only in patients who have developed nephri-
tis [47, 48]. It seems though that deterioration of renal function is not associated 
with the serum levels of Gd-IgA1 and IgA-IgG complexes. Recently, a French mul-
ticenter prospective study showed that urinary IgA concentration can be used as an 
additional index in order to improve patient risk stratification for poor outcome at 
disease onset. This is an important finding, since only a small percentage of IgAV 
patients finally develop severe deterioration of renal function and can benefit from 
intensive care, monitoring and follow-up and for the time IgAV outcome assessment 
is based on conventional clinical factors [48].
13
Biomarkers in Renal Vasculitis
DOI: http://dx.doi.org/10.5772/intechopen.86489
22. Cluster of differentiation (CD) antigens
Concerning CD antigens that could be used as biomarkers, CD89 has been found 
to be useful in the assessment of IgAV. CD89 is the human myeloid specific IgA 
Fc receptor. It is expressed on neutrophils, eosinophils, monocytes/macrophages, 
dendritic cells and Kupffer cells [49, 50]. In IgAN patients, cleavage of the CD89 
extracellular domain and release of IgA-soluble CD89 (IgA-sCD89) complexes is 
caused by the binding of IgA to CD89. Therefore, high levels of circulating IgA-
sCD89 complexes are observed in these patients. The complexes are trapped in the 
mesangium by the transferin receptor. Their deposition, as well as mesangial activa-
tion, is facilitated by transglutaminase 2 (TG2) [48, 51]. IgAV patients demonstrate 
decreased expression of CD89 at their monocyte and granulocyte cell surface. This 
finding is combined with increased blood concentration of IgA-sCD89 complexes. 
Urinary levels of these complexes are more elevated in individuals who develop 
nephritis [47, 48]. Furthermore, according to the findings of a 2016 multicenter 
study, urinary CD89 and TG2 concentrations are significantly lower in patients with 
active IgA vasculitis with nephritis (IgAV-N) compared to individuals whose disease 
has gone into complete or partial remission. More specifically, urinary CD89 and 
TG2 levels were found to be positively correlated with each other and negatively 
correlated with the level of proteinuria. It has been proposed that this decrease is 
consistent with the reduction in CD89 and TG2 urinary excretion as a result of the 
mononuclear-cell mediated inflammatory reaction that is induced by IgA-sCD89 
deposition in the kidney. During this active phase, large multimolecular complexes 
containing CD89, TG2, CD71 and IgA1 are stabilized on the mesangial cell surface, 
thus causing CD89 and TG2 molecules to remain in the renal tissue. Interestingly, 
there seems to be a stronger negative correlation between proteinuria and urinary 
CD89 levels in comparison to TG2 levels, thus suggesting that CD89 might decrease 
earlier in the urine of patients with IgAV-N [51].
CD62L (L-selectin) and CD11b are also found to be upregulated in IgAN 
patients and are considered to be involved in IgAV pathogenesis. CD62L, is an adhe-
sion molecule observed on the neutrophil surface that mediates the initial adhesion 
of neutrophils to the endothelium and could consequently be important in the 
early development of IgAV. CD11b is a predominant β2 integrin, also expressed on 
neutrophils. High CD11b and IgA levels possibly promote vascular damage through 
induction of antibody-dependent cellular toxicity (ADCC) [52].
23. Cytokines and other inflammatory factors
Regarding pro-inflammatory cytokines, IgAV patients with or without nephritis 
present high serum concentrations of IL-1b, IL-6 and IL-8 compared with normal 
controls, with the increase in IL-6 and IL-8 levels being very significant in individuals 
with renal involvement. Urine IL-6, IL-8 and IL-10 concentrations appear to be more 
elevated in IgAV-N patients, in the same way as in patients with IgAN [53, 54]. These 
cytokines possibly play a role in mesangial cell activation, proliferation, crescent 
formation and glomerulosclerosis. Additionally, increase in IL-6 blood concentration 
seems to be an index of the acute phase of IgAV [47, 48]. Tumor necrosis factor (TNF) 
blood levels, that have also been associated with the development of interstitial 
fibrosis and tubular atrophy regardless of renal function, are higher in IgAV patients 
who present with nephritis [47]. Furthermore, several other inflammatory param-
eters, including C-reactive protein (CRP), Serum Amyloid A (SAA) and Neutrophil-
Lymphocyte ratio (NLR), also seem to be upregulated in IgAV patients in comparison 
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to healthy individuals [55]. Of all these inflammatory indexes, NLR seems to present 
the strongest diagnostic value concerning the development of extracutaneal mani-
festations in adult IgAV (gastrointestinal and/or renal). The severity of the systemic 
involvement has been found to be associated with high NLR before treatment [56]. 
There is also a possible connection between high SAA levels also has a possible con-
nection with the presence of gastrointestinal manifestations [52].
24. Neutrophil gelatinase-associated lipocalin (NGAL)
NGAL protein, a member of the lipocalin superfamily initially found in 
activated neutrophils, is produced in various cell types including renal tubules. 
It is a factor promoting kidney cellular proliferation and differentiation that is 
significantly upregulated in response to epithelial injury, thus serving as an index 
of kidney damage [47, 57]. It can possibly predict the appearance of acute renal 
impairment and the acute deterioration of unstable nephropathies. Furthermore, 
it may also be implicated in the pathophysiology of some chronic kidney disease 
(CKD) conditions, such as polycystic kidney disease and glomerulonephritis, while 
its levels are directly associated with the degree of renal damage [25]. In IgAV, 
NGAL concentrations seem to be high in both patients with and without nephritis, 
while its levels in urine, found more elevated in patients with nephritis, are useful in 
distinguishing them from individuals without kidney impairment [47, 48].
25. Soluble transferin receptor (sTfR)
sTfR consists of a single polypeptide chain and has been found to be upregu-
lated in IgAV-N and IgAN patients, perhaps as a result of IgA1 polymer-mediated 
induction. Its overexpression is thought to be associated with the disease severity. 
Normally, it cannot cross the glomerular membrane because of its molecular size. 
However, when non-selective glomerular proteinuria is present, it is possible that 
the molecule can passively cross the membrane and then be detected in the urine. 
Interestingly, it has been found that in IgAV-N and IgAN patients the sTfR/creati-
nine ratio is higher than the ratio measured in healthy individuals or patients with 
other glomerulopathies. Therefore, it can possibly be used as a non-invasive tool to 
distinguish those two diseases from other pathologies that cause proteinuria. It has 
also been proposed that sTfR can additionally be further evaluated as a potential 
prognostic and activity marker for IgAV-N and IgAN [58].
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